Evidence map›Paper›PMID 36251136›Full record

ReviewAnnals of intensive care2022

Intravenous fluid therapy in patients with severe acute pancreatitis admitted to the intensive care unit: a narrative review.

Andrea Crosignani, Stefano Spina, Francesco Marrazzo, Stefania Cimbanassi, Manu L N G Malbrain, Niels Van Regenmortel, Roberto Fumagalli, Thomas Langer

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Annals of intensive care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 5 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Impact of 24-hour urine output trajectories on intra-abdominal hypertension risk in acute pancreatitis patients: Insights from MIMIC-IV database.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Andrea Crosignani *School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Stefano Spina *School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Francesco MarrazzoSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Stefania CimbanassiGeneral Surgery and Trauma Team, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Manu L N G MalbrainFirst Department of Anaesthesia and Intensive Therapy, Medical University of Lublin, Lublin, Poland.
Niels Van RegenmortelDepartment of Intensive Care Medicine, Antwerp University Hospital, Antwerp, Belgium.
Roberto FumagalliSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Thomas LangerSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy. thomas.langer@unimib.it.ORCID http://orcid.org/0000-0002-9725-8520
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITAntwerp University Hospital · BEMedical University of Lublin · PLUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with acute pancreatitis (AP) often require ICU admission, especially when signs of multiorgan failure are present, a condition that defines AP as severe. This disease is characterized by a massive pancreatic release of pro-inflammatory cytokines that causes a systemic inflammatory response syndrome and a profound intravascular fluid loss. This leads to a mixed hypovolemic and distributive shock and ultimately to multiorgan failure. Aggressive fluid resuscitation is traditionally considered the mainstay treatment of AP. In fact, all available guidelines underline the importance of fluid therapy, particularly in the first 24-48 h after disease onset. However, there is currently no consensus neither about the type, nor about the optimal fluid rate, total volume, or goal of fluid administration. In general, a starting fluid rate of 5-10 ml/kg/h of Ringer's lactate solution for the first 24 h has been recommended. Fluid administration should be aggressive in the first hours, and continued only for the appropriate time frame, being usually discontinued, or significantly reduced after the first 24-48 h after admission. Close clinical and hemodynamic monitoring along with the definition of clear resuscitation goals are fundamental. Generally accepted targets are urinary output, reversal of tachycardia and hypotension, and improvement of laboratory markers. However, the usefulness of different endpoints to guide fluid therapy is highly debated. The importance of close monitoring of fluid infusion and balance is acknowledged by most available guidelines to avoid the deleterious effect of fluid overload. Fluid therapy should be carefully tailored in patients with severe AP, as for other conditions frequently managed in the ICU requiring large fluid amounts, such as septic shock and burn injury. A combination of both noninvasive clinical and invasive hemodynamic parameters, and laboratory markers should guide clinicians in the early phase of severe AP to meet organ perfusion requirements with the proper administration of fluids while avoiding fluid overload. In this narrative review the most recent evidence about fluid therapy in severe AP is discussed and an operative algorithm for fluid administration based on an individualized approach is proposed.

Indexed as

Acute pancreatitisCritical illnessCrystalloid solutionsFluid therapyRinger’s lactate

Identifiers

PMID36251136
PMCPMC9576837
OpenAlexW4306410866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.